Discontinued — last reported Q4 '19
Linde Other Intangible Assets, Net decreased by 1.2% to $11.93B in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 1.5%, from $12.11B to $11.93B. Over 4 years (FY 2020 to FY 2024), Other Intangible Assets, Net shows a downward trend with a -8.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
A high value indicates a strong portfolio of intellectual property, while a declining value may signal the approaching expiration of key patents.
This includes identifiable non-physical assets such as patents, trademarks, licenses, and acquired drug rights, net of a...
Crucial for comparing the strength of drug pipelines and competitive advantages among pharmaceutical peers.
other_intangibles_net| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $14.49B | $14.05B | $13.80B | $13.51B | $12.63B | $11.81B | $12.42B | $12.64B | $12.51B | $12.09B | $12.40B | $12.00B | $11.85B | $12.11B | $11.33B | $11.56B | $12.08B | $11.93B |
| QoQ Change | — | -3.1% | -1.8% | -2.1% | -6.5% | -6.5% | +5.2% | +1.8% | -1.0% | -3.3% | +2.5% | -3.2% | -1.2% | +2.2% | -6.5% | +2.0% | +4.5% | -1.2% |
| YoY Change | — | — | — | — | -12.8% | -15.9% | -10.0% | -6.4% | -1.0% | +2.4% | -0.2% | -5.0% | -5.3% | +0.2% | -8.6% | -3.7% | +1.9% | -1.5% |
We use cookies for analytics. See our Privacy and Cookie Policy.